IMR Press / FBE / Volume 1 / Issue 1 / DOI: 10.2741/E2

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Green tea and prostate cancer: from bench to clinic
Show Less
1 Department of Urology and Nutrition, Case Western Reserve University, Clevelamd, OH 44106, USA
2 University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA
3 Case Comprehensive Cancer Center, Cleveland, Ohio 44106, USA
Front. Biosci. (Elite Ed) 2009, 1(1), 13–25;
Published: 1 June 2009

Green tea, the most popular beverage next to water, is a rich source of tea catechins and has potential to be developed as a chemopreventive agent for prostate cancer. For centuries it has been used in traditional medicine in Far-East countries. Male populations in these countries where large quantities of green tea are consumed on regular basis have the lowest incidence of prostate cancer. In this review, after a description of prostate cancer and several risk factors associated with the disease, we evaluated studies reported with green tea or its major constituent, (-)-epigallocatechin-3-gallate in inhibition of prostate cancer. This review provides an in-depth overview of various biochemical and signaling pathways affected by green tea in in vivo and in vitro models of prostate cancer. This is followed by a comprehensive discussion of the epidemiological studies and some ongoing clinical trials with green tea catechins. The review concludes with a brief discussion of the future direction and development of clinical trials employing green tea catechins which could be developed for prevention and/or intervention of prostate cancer.

Back to top